Y Intercept Hong Kong Ltd Acquires 16,115 Shares of Illumina, Inc. (NASDAQ:ILMN)

Y Intercept Hong Kong Ltd lifted its holdings in Illumina, Inc. (NASDAQ:ILMN) by 506.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 19,300 shares of the life sciences company’s stock after acquiring an additional 16,115 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Illumina were worth $2,579,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Versant Capital Management Inc raised its position in shares of Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after acquiring an additional 146 shares in the last quarter. Golden State Wealth Management LLC acquired a new stake in shares of Illumina in the 4th quarter valued at about $32,000. TD Private Client Wealth LLC grew its stake in shares of Illumina by 58.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after buying an additional 141 shares during the period. V Square Quantitative Management LLC grew its stake in shares of Illumina by 50.6% in the 4th quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company’s stock valued at $52,000 after buying an additional 132 shares during the period. Finally, First Horizon Advisors Inc. grew its stake in shares of Illumina by 73.5% in the 4th quarter. First Horizon Advisors Inc. now owns 439 shares of the life sciences company’s stock valued at $59,000 after buying an additional 186 shares during the period. 89.42% of the stock is owned by institutional investors.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $93.96 on Tuesday. Illumina, Inc. has a twelve month low of $92.20 and a twelve month high of $156.66. The stock’s 50 day moving average price is $126.97 and its 200-day moving average price is $133.99. The company has a market capitalization of $14.88 billion, a PE ratio of -12.23, a PEG ratio of 1.60 and a beta of 1.10. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, equities analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on ILMN shares. JPMorgan Chase & Co. raised their target price on Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Royal Bank of Canada reduced their target price on Illumina from $250.00 to $247.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Morgan Stanley reduced their target price on Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 11th. Guggenheim reduced their target price on Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Finally, Canaccord Genuity Group reduced their target price on Illumina from $145.00 to $135.00 and set a “hold” rating for the company in a research note on Friday, February 7th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $159.45.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.